Curcumin: From Ancient Spice to Modern Anti-Viral Drug in COVID-19 Pandemic

Subhan, Fazli; Zeeshan, Muhammad; Haider, Adnan; Tauseef, Isfahan; Haleem, Kashif Syed; Ibrahim, Ahmed Saadi

doi:10.37185/lns.1.1.137

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the several unique properties of curcumin and its beneficial effects on different aspects of human health, several reviews and also some clinical trials have recently suggested that curcumin might have beneficial effects on signs and symptoms of COVID-19 [ 6 , 19 , 23 – 27 ]. Results from clinical trials showed that curcumin as a natural polyphenolic compound could be a potential treatment for COVID-19 infection [ 19 , 23 , 25 , 28 ]. A review study reported some of the potential effects of curcumin such as inhibiting the entry of viruses to the cell, inhibiting encapsulation of the virus and viral protease [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Askari

Sahebkar

Soleimani

et al. 2022

Trials

View full text Add to dashboard Cite

Background COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. Methods Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. Results Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). Conclusion The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. Trial registration Iranian Registry of Clinical Trials IRCT20121216011763N46. 2020-10-31

show abstract

Section: Introductionmentioning

confidence: 99%

The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Askari

Sahebkar

Soleimani

et al. 2022

Trials

View full text Add to dashboard Cite

show abstract

“…Curcumin can interact with spike proteins or angiotensin 2 (ACE2) proteins in the signalling pathway induced by COVID-19. Curcumin also inhibits several important signalling pathways in viral infection, such as transcription factors (NF-κB, signal transducer and activator of transcription 3 (STAT-3), Vnt/b-catenin, nuclear factor E2-related factor (Nrf2), p38/MAPK, and virus-induced inflammation by modulating the manifestation of various factors (IL-10, Interleukin-18 (IL-18), IL-6, tumour necrosis factor (TNF) α/β and COX-2) in COVID-19 [ 153 , 154 ]. Valizadeha et al investigated the effect of nanocurcumin on the modulation of inflammatory cytokines in patients with COVID-19.…”

Section: Biological Activities Of Curcuminmentioning

confidence: 99%

Curcumin: Biological Activities and Modern Pharmaceutical Forms

et al. 2022

View full text Add to dashboard Cite

Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-hepta-1,6-diene-3,5-dione) is a natural lipophilic polyphenol that exhibits significant pharmacological effects in vitro and in vivo through various mechanisms of action. Numerous studies have identified and characterised the pharmacokinetic, pharmacodynamic, and clinical properties of curcumin. Curcumin has an anti-inflammatory, antioxidative, antinociceptive, antiparasitic, antimalarial effect, and it is used as a wound-healing agent. However, poor curcumin absorption in the small intestine, fast metabolism, and fast systemic elimination cause poor bioavailability of curcumin in human beings. In order to overcome these problems, a number of curcumin formulations have been developed. The aim of this paper is to provide an overview of recent research in biological and pharmaceutical aspects of curcumin, methods of sample preparation for its isolation (Soxhlet extraction, ultrasound extraction, pressurised fluid extraction, microwave extraction, enzyme-assisted aided extraction), analytical methods (FTIR, NIR, FT-Raman, UV-VIS, NMR, XRD, DSC, TLC, HPLC, HPTLC, LC-MS, UPLC/Q-TOF-MS) for identification and quantification of curcumin in different matrices, and different techniques for developing formulations. The optimal sample preparation and use of an appropriate analytical method will significantly improve the evaluation of formulations and the biological activity of curcumin.

show abstract

“…A study has shown that curcumin, in addition to its antioxidant effects by activating the Nrf2 pathway and induction of Glutathione (GSH) production, inactivates influenza A virus infection and alleviates the impacts of COVID-19 [7]. Many studies have also shown that sulforaphane (SFN), a natural compound derived from broccoli sprouts, suppresses viral replication in respiratory diseases such as influenza A and hepatitis C virus (HCV) and Herpes simplex virus 1 (HSV-1).…”

mentioning

confidence: 99%